| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.4 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.4 |
| mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.4 |
| mRNA | ML312 | CTRPv2 | pan-cancer | AAC | -0.063 | 0.4 |